Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2012;7(5):e35778.
doi: 10.1371/journal.pone.0035778. Epub 2012 May 10.

Implementation of anaphylaxis management guidelines: a register-based study

Affiliations
Clinical Trial

Implementation of anaphylaxis management guidelines: a register-based study

Linus Grabenhenrich et al. PLoS One. 2012.

Abstract

Background: Anaphylaxis management guidelines recommend the use of intramuscular adrenaline in severe reactions, complemented by antihistamines and corticoids; secondary prevention includes allergen avoidance and provision of self-applicable first aid drugs. Gaps between recommendations and their implementation have been reported, but only in confined settings. Hence, we analysed nation-wide data on the management of anaphylaxis, evaluating the implementation of guidelines.

Methods: Within the anaphylaxis registry, allergy referral centres across Germany, Austria and Switzerland provided data on severe anaphylaxis cases. Based on patient records, details on reaction circumstances, diagnostic workup and treatment were collected via online questionnaire. Report of anaphylaxis through emergency physicians allowed for validation of registry data.

Results: 2114 severe anaphylaxis patients from 58 centres were included. 8% received adrenaline intravenously, 4% intramuscularly; 50% antihistamines, and 51% corticoids. Validation data indicated moderate underreporting of first aid drugs in the Registry. 20% received specific instructions at the time of the reaction; 81% were provided with prophylactic first aid drugs at any time.

Conclusion: There is a distinct discrepancy between current anaphylaxis management guidelines and their implementation. To improve patient care, a revised approach for medical education and training on the management of severe anaphylaxis is warranted.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: This work was supported by unrestricted grants from Allergopharma and ALK-Abello. There are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.

Figures

Figure 1
Figure 1. Drugs used for emergency treatment of anaphylaxis, by cause.
Only assured cases. All application routes, error bars indicate 95% confidence intervals.
Figure 2
Figure 2. Drugs used for emergency treatment of anaphylaxis, by age.
Dashed lines indicate proportion of patients having received inhalation (adrenaline) or oral (antihistamine, corticoid) treatment only, error bars indicate 95% confidence intervals.
Figure 3
Figure 3. Drugs used by emergency physicians for initial treatment of anaphylaxis.
Firsthand report (EPs) vs. self report (anaphylaxis registry). Parenteral application routes only. * Weighted for age, cause and severity distribution in anaphylaxis registry, Berlin catchment area.
Figure 4
Figure 4. First time receiving prophylactic first aid drugs following severe anaphylaxis.

References

    1. Ring J, Behrendt H. Anaphylaxis and anaphylactoid reactions. Classification and pathophysiology. Clin Rev Allergy Immunol. 1999;17:387–399. - PubMed
    1. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113:832–836. - PubMed
    1. Alves B, Sheikh A. Age specific aetiology of anaphylaxis. Archives of disease in childhood. 2001;85:348. - PMC - PubMed
    1. Simons FE, Sampson HA. Anaphylaxis epidemic: fact or fiction? J Allergy Clin Immunol. 2008;122:1166–1168. - PubMed
    1. Lieberman P, Camargo CA, Bohlke K, Jick H, Miller RL, et al. Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group. Ann Allergy Asthma Immunol. 2006;97:596–602. - PubMed

Publication types